Recent News

• 10.29.2026 - Milestone Scientific Provides Major Commercial Growth Update as CompuFlo® Expands Across 30 Million+ Annual Global Epidural Procedures
• 09.29.2026 - Milestone Scientific Highlights Building a Scalable Growth Platform for CompuFlo® Medical Business
• 09.16.2026 - Milestone Scientific Announces Pain and Spine Specialists and Dr. Sudhir Rao as CompuFlo® Development Partner and Advisor
• 08.26.2026 - Milestone Scientific Achieves Debt-Free Balance Sheet Through Debt-to-Equity Conversion by Three Directors
• 08.14.2026 - Milestone Scientific Reports Financial Results for Second Quarter 2026
• 08.06.2026 - Milestone Scientific Schedules Second Quarter 2026 Financial Results Conference Call
• 08.04.2026 - Milestone Scientific Announces Strategic Federal Distribution Partnership with Red One Medical to Expand Commercial Access for the CompuFlo® Epidural System
• 07.15.2026 - Milestone Scientific Launches First Phase of AI Strategy with Pilot Debut of Milo, an AI-enabled Digital Engagement Platform, at ASPN 2026
• 07.01.2026 - Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY
• 06.25.2026 - Milestone Scientific Strengthens Board to Support Next Phase of Growth

Recent Filings

• 09.28.2026 - EFFECT Notice of Effectiveness
• 09.18.2026 - S-3/A Registration statement under Securities Act of 1933
• 09.08.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 09.08.2026 - S-3 Registration statement under Securities Act of 1933
• 08.13.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.31.2026 - 8-K Current report
• 07.29.2026 - 8-K Current report
• 07.29.2026 - EX-99.1 EX-99.1
• 06.25.2026 - 8-K Current report
• 06.25.2026 - EX-99.1 EX-99.1